ImmunoBiochem is developing antibody-directed protein degraders for autoimmune disease
ImmunoBiochem is designing a treatment to reach disease-driving immune cells and act on proteins inside them. Its lead candidate, IMB216P, combines an antibody-directed approach with a payload intended to degrade two proteins involved in immune signalling. The idea addresses a difficult trade-off in autoimmune care: controlling harmful immune activity without unnecessarily weakening the body's defences.
A targeted approach to immune cells
A 2022 National Academies report notes that people with lupus can be vulnerable to infection during immunosuppressive treatment. Targeted treatments also exist for the disease.
ImmunoBiochem describes IMB216P as a degrader-antibody conjugate: an antibody is paired with a synthetic payload designed to break down selected proteins. The company identifies the antibody target as CD127, also called IL7RA, and the payload targets as JAK1 and TYK2.
The company aims to influence disease-driving T cells without broadly suppressing the immune system. That is a development goal, not an established patient benefit.
For a drug developer, the distinction matters: a treatment that can reach a particular cell population and affect signalling within it could offer another way to address autoimmune disease. Whether this candidate can do so safely and effectively in patients remains to be established.